PATENT CLAIM ANALYSIS

Application Number: 15779611
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "327000"]

Abstract:
The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.

Claim (Index 25):
The pharmaceutical composition according to  claim 19  has the amount in Table C below: TABLE C COMPOSITION Formula Unit Formula, (HBr lyophilized (mg/mL) Nominal Fill formulation) 2 mg/mL (mg/13 mL) Danirixin, HBr. \u20032.46 mg* 31.98 mg ACTIVE SUBSTANCE B-CYCLODEXTRIN \u200240.0 mg 520.0 mg SULFOBUTYLETHER, CAPTISOL* MANNITOL \u2003\u200950 mg 650.0 mg CITRIC ACID 0.655 mg 8.515 mg SODIUM CITRATE 0.555 mg 7.215 mg SODIUM HYDROXIDE QS QS HYDROCHLORIC QS QS ACID pH 3.9 \u2014 *QS refers to \u201cquantity sufficient\u201d to fill the vial to the nominal fill (or volume). *indicates 2 mg/mL that has been adjusted for the salt factor of 1.228 = 2.46 mg/mL

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.39394
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14668683', '10553139', '13704145', '12370794', '16073580']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7216651147122451
- 35 USC 102 Novelty (BERT): 0.5045311375575887
- Combined Prediction Score: 0.6999517169967795
- Mean Citation Score: 172.468098
- Max Citation Score: 174.8063
- Similarity Product: 107.80864965892437

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test